Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus LORATADINE REDIDOSE.
LIVOSTIN vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine
Antihistamine